These findings suggested that neoadjuvant and adjuvant chemotherapy, radiotherapy, immunotherapy, and ERBB-family-based target therapy could be ideal choices for BLCA patients with high MTHFD2 expression. This evidence concerns the gene EGFR and bladder transitional cell carcinoma.